{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:33:23Z","timestamp":1790627603072,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["L244024"],"award-info":[{"award-number":["L244024"]}]},{"name":"the Beijing High-Level Innovation and Entrepreneurship Talent Support Program leading talent projects","award":["G202512054"],"award-info":[{"award-number":["G202512054"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473199"],"award-info":[{"award-number":["82473199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05110-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T02:57:53Z","timestamp":1774407473000},"page":"3359-3377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stage-specific associations of HER2 overexpression with clinical and pathological features in bladder cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Citing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"5110_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr308","author":"MJ Rodrigues","year":"2011","unstructured":"Rodrigues MJ, Albiges-Sauvin L, Wassermann J, Cottu PH (2011) Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdr308","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"5110_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0305-7372(10)70014-1","volume":"36","author":"F De Vita","year":"2010","unstructured":"De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M (2010) Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev 36(Suppl 3):S11-15. https:\/\/doi.org\/10.1016\/S0305-7372(10)70014-1","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"5110_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdz076","volume":"30","author":"J Veeraraghavan","year":"2019","unstructured":"Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC et al (2019) A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol 30(6):927\u2013933. https:\/\/doi.org\/10.1093\/annonc\/mdz076","journal-title":"Ann Oncol"},{"issue":"16","key":"5110_CR4","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CEJ, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England J Med 353(16):1673\u20131684","journal-title":"New England J Med"},{"issue":"9742","key":"5110_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y Bang","year":"2010","unstructured":"Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 376(9742):687\u2013697","journal-title":"Lancet (London, England)."},{"issue":"4","key":"5110_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson ABR et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"issue":"1","key":"5110_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D Oh","year":"2020","unstructured":"Oh D, Bang Y (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"5110_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/annonc\/mdp488","volume":"21","author":"M La\u00e9","year":"2010","unstructured":"La\u00e9 M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21(4):815\u2013819. https:\/\/doi.org\/10.1093\/annonc\/mdp488","journal-title":"Ann Oncol"},{"issue":"2","key":"5110_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jncc.2023.02.003","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y et al (2023) Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent 3(2):121\u2013128. https:\/\/doi.org\/10.1016\/j.jncc.2023.02.003","journal-title":"J Natl Cancer Cent"},{"issue":"23","key":"5110_CR10","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H et al (2025) Disitamab Vedotin plus Toripalimab in HER2-expressing advanced urothelial cancer. N Engl J Med 393(23):2324\u20132337. https:\/\/doi.org\/10.1056\/NEJMoa2511648","journal-title":"N Engl J Med"},{"issue":"12","key":"5110_CR11","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z, Shi Y, Luo H, Han W et al (2024) Efficacy and safety of Disitamab Vedotin in patients with Human Epidermal Growth Factor Receptor 2-Positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two Phase II clinical trials. J Clin Oncol 42(12):1391\u20131402. https:\/\/doi.org\/10.1200\/JCO.22.02912","journal-title":"J Clin Oncol"},{"issue":"2","key":"5110_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","volume":"60","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN (2011) Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 60(2):350\u2013357. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.035","journal-title":"Eur Urol"},{"key":"5110_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","author":"D Raggi","year":"2025","unstructured":"Raggi D, Crupi E, Pederzoli F, Martini A, Briganti A, Alhalabi O et al (2025) HER2 and urothelial carcinoma: current understanding and future directions. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-025-01075-x","journal-title":"Nat Rev Urol"},{"issue":"4","key":"5110_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ng.3503","volume":"48","author":"HA Al-Ahmadie","year":"2016","unstructured":"Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A et al (2016) Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet 48(4):356\u2013358. https:\/\/doi.org\/10.1038\/ng.3503","journal-title":"Nat Genet"},{"issue":"6","key":"5110_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH et al (2015) Genomic characterization of upper tract urothelial carcinoma. Eur Urol 68(6):970\u2013977. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.039","journal-title":"Eur Urol"},{"issue":"8","key":"5110_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7\u2013H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56(8):1173\u20131182","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"5110_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","volume":"4","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina E, Shim SR, Mori K, D\u2019Andrea D, Soria F, Rajwa P et al (2021) Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: a Systematic Review and Network Meta-analysis. Eur Urol Oncol. 4(6):927\u2013942","journal-title":"Eur Urol Oncol."},{"issue":"12","key":"5110_CR18","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1007\/s11864-023-01151-7","volume":"24","author":"EJ Miller","year":"2023","unstructured":"Miller EJ, Galsky MD (2023) Precision medicine in urothelial carcinoma: current markers to guide treatment and promising future directions. Curr Treat Options Oncol 24(12):1870\u20131888. https:\/\/doi.org\/10.1007\/s11864-023-01151-7","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"5110_CR19","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","volume":"31","author":"A Moktefi","year":"2018","unstructured":"Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P et al (2018) Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Mod Pathol 31(8):1270\u20131281. https:\/\/doi.org\/10.1038\/s41379-018-0023-9","journal-title":"Mod Pathol"},{"key":"5110_CR20","first-page":"160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ (Clinical Research Ed.). 372:160","journal-title":"BMJ (Clinical Research Ed.)."},{"issue":"7414","key":"5110_CR21","first-page":"557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 327(7414):557\u2013560","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"11","key":"5110_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JPT (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11):1559\u20131573","journal-title":"Stat Med"},{"issue":"17","key":"5110_CR23","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J (2003) Improved tests for a random effects meta-regression with a single covariate. Stat Med 22(17):2693\u20132710","journal-title":"Stat Med"},{"issue":"9","key":"5110_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605. https:\/\/doi.org\/10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"5110_CR25","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3346\/jkms.2015.30.8.1068","volume":"30","author":"SD Lim","year":"2015","unstructured":"Lim SD, Cho YM, Choi G, Park HK, Paick SH, Kim WY et al (2015) Clinical significance of substaging and HER2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder. J Korean Med Sci 30(8):1068\u20131077. https:\/\/doi.org\/10.3346\/jkms.2015.30.8.1068","journal-title":"J Korean Med Sci"},{"issue":"12","key":"5110_CR26","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","volume":"33","author":"W Ding","year":"2015","unstructured":"Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z et al (2015) Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33(12):1951\u20131957. https:\/\/doi.org\/10.1007\/s00345-015-1557-9","journal-title":"World J Urol"},{"issue":"4","key":"5110_CR27","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/2090598X.2020.1814183","volume":"18","author":"V Agrawal","year":"2020","unstructured":"Agrawal V, Bharti N, Pandey R (2020) Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: identification of patients for targeted therapy. Arab J Urol 18(4):267\u2013272. https:\/\/doi.org\/10.1080\/2090598X.2020.1814183","journal-title":"Arab J Urol"},{"issue":"2","key":"5110_CR28","first-page":"11313","volume":"95","author":"MY Ali","year":"2023","unstructured":"Ali MY, Aboelsaad AY, AbdelGawad AM, Abouelgreed TA, ElGammal AA, Ghoneimy OM et al (2023) HER2\/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones. Arch Ital Urol Androl 95(2):11313","journal-title":"Arch Ital Urol Androl"},{"issue":"4","key":"5110_CR29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","volume":"7","author":"X Tan","year":"2024","unstructured":"Tan X, Liu Z, Cai T, Wang Y, Wu Z, Qin Z et al (2024) Prognostic significance of HER2 expression in patients with Bacillus Calmette-Gu\u00e9rin-exposed non-muscle-invasive bladder cancer. Eur Urol Oncol 7(4):760\u2013769. https:\/\/doi.org\/10.1016\/j.euo.2023.10.003","journal-title":"Eur Urol Oncol"},{"key":"5110_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1243118","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Ji Y, Liu Y, Du P, Ma J, Yang X et al (2023) The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study. Front Oncol 13:1243118. https:\/\/doi.org\/10.3389\/fonc.2023.1243118","journal-title":"Front Oncol"},{"key":"5110_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301510","volume":"14","author":"W Nam","year":"2023","unstructured":"Nam W, Chae HK, Jung Y, Kang H, Park M, Choi A et al (2023) HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer. Front Immunol 14:1301510. https:\/\/doi.org\/10.3389\/fimmu.2023.1301510","journal-title":"Front Immunol"},{"key":"5110_CR32","doi-asserted-by":"publisher","unstructured":"Chen Z. Prognostic significance of HER-2 expression in patients with non-muscular invasive bladder cancer treated with gemcitabine infusion chemotherapy, Kunming Medical University; 2024. Available from: https:\/\/link.cnki.net\/doi\/https:\/\/doi.org\/10.27202\/d.cnki.gkmyc.2024.000469","DOI":"10.27202\/d.cnki.gkmyc.2024.000469"},{"issue":"04","key":"5110_CR33","first-page":"7","volume":"7","author":"H Wang","year":"2015","unstructured":"Wang H, Li C, Jiang G, Ding W, Gou Y, Sun C et al (2015) HER2 as an Independent Prognostic Indicator for Predicting Recurrence and Progression in Non-muscle Invasive Bladder Cancer. Chinense J Urol 7(04):7\u201312","journal-title":"Chinense J Urol"},{"issue":"8","key":"5110_CR34","first-page":"2440","volume":"7","author":"RE Jimenez","year":"2001","unstructured":"Jimenez RE, Hussain M, Bianco FJJ, Vaishampayan U, Tabazcka P, Sakr WA et al (2001) Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7(8):2440\u20132447","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5110_CR35","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ijc.10731","volume":"102","author":"S Kr\u00fcger","year":"2002","unstructured":"Kr\u00fcger S, Weitsch G, B\u00fcttner H, Matthiensen A, B\u00f6hmer T, Marquardt T et al (2002) HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 102(5):514\u2013518","journal-title":"Int J Cancer"},{"issue":"2","key":"5110_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11255-007-9283-x","volume":"40","author":"SB Kolla","year":"2008","unstructured":"Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN et al (2008) Prognostic significance of Her2\/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 40(2):321\u2013327","journal-title":"Int Urol Nephrol"},{"key":"5110_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2703-5","volume":"16","author":"T Nedjadi","year":"2016","unstructured":"Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A et al (2016) Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer 16:653. https:\/\/doi.org\/10.1186\/s12885-016-2703-5","journal-title":"BMC Cancer"},{"issue":"4","key":"5110_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3349\/ymj.2016.57.4.831","volume":"57","author":"S Lim","year":"2016","unstructured":"Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho DY et al (2016) Fibroblast Growth Factor Receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma. Yonsei Med J 57(4):831\u2013839. https:\/\/doi.org\/10.3349\/ymj.2016.57.4.831","journal-title":"Yonsei Med J"},{"key":"5110_CR39","doi-asserted-by":"publisher","unstructured":"Wang J. Correlation between HER2 and clinical pathological molecular typing of urothelial bladder cancer, Anhui Medical University; 2019. Available from: https:\/\/link.cnki.net\/doi\/https:\/\/doi.org\/10.26921\/d.cnki.ganyu.2019.000240","DOI":"10.26921\/d.cnki.ganyu.2019.000240"},{"key":"5110_CR40","doi-asserted-by":"publisher","unstructured":"Liu Z. Clinical prognostic correlation of molecular subtypes in muscular invasive bladder cancer, Hainan Medical University; 2023. Available from: https:\/\/link.cnki.net\/doi\/https:\/\/doi.org\/10.27952\/d.cnki.ghnyx.2023.000198","DOI":"10.27952\/d.cnki.ghnyx.2023.000198"},{"issue":"08","key":"5110_CR41","first-page":"746","volume":"31","author":"YCCG Leng Feiyun","year":"2024","unstructured":"Leng Feiyun YCCG (2024) Correlation between p -AKT, VEGF, HER -2 expression and prognosis of bladder invasive urothelial carcinoma. Chinese J Diagn Pathol 31(08):746\u2013751","journal-title":"Chinese J Diagn Pathol"},{"key":"5110_CR42","doi-asserted-by":"publisher","unstructured":"Li R. Analysis of the connections between molecular subtypes and clinicopathological characteristics of urinary tract carcinoma of the bladder, Kunming Medical University; 2024. Available from: https:\/\/link.cnki.net\/doi\/https:\/\/doi.org\/10.27202\/d.cnki.gkmyc.2024.000171","DOI":"10.27202\/d.cnki.gkmyc.2024.000171"},{"key":"5110_CR43","doi-asserted-by":"publisher","unstructured":"Zhou H. Clinicopathologic characterization of invasive urothelial carcinoma of the bladder with low HER2 expression, Gannan Medical University; 2025. Available from: https:\/\/link.cnki.net\/doi\/https:\/\/doi.org\/10.27959\/d.cnki.ggnyx.2025.000225","DOI":"10.27959\/d.cnki.ggnyx.2025.000225"},{"key":"5110_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1355081","volume":"15","author":"K Zhu","year":"2024","unstructured":"Zhu K, Chang Y, Zhao D, Guo A, Cao J, Wu C et al (2024) Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients. Front Pharmacol 15:1355081. https:\/\/doi.org\/10.3389\/fphar.2024.1355081","journal-title":"Front Pharmacol"},{"issue":"2","key":"5110_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.euf.2024.05.018","volume":"10","author":"E Nally","year":"2024","unstructured":"Nally E, Young M, Wells C, Fairhead R, Baines K, Cheney-Lowe H et al (2024) Is HER2 the new NECTIN4 in advanced urothelial cancer? Eur Urol Focus 10(2):219\u2013221. https:\/\/doi.org\/10.1016\/j.euf.2024.05.018","journal-title":"Eur Urol Focus"},{"key":"5110_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04057-x","author":"M Yang","year":"2025","unstructured":"Yang M, Yao Y, Wang K, Qi L, Yang B, Khudadad M et al (2025) Clinicopathological characteristics and prognostic significance of HER2 status evaluation in patients with urothelial carcinoma: a retrospective single-center experience in China. Virchows Archiv: Int J Pathol. https:\/\/doi.org\/10.1007\/s00428-025-04057-x","journal-title":"Virchows Archiv: Int J Pathol"},{"issue":"11","key":"5110_CR47","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.21037\/tau-24-354","volume":"13","author":"X Huang","year":"2024","unstructured":"Huang X, Li S, Yang T, Ma D, Cai H, Xu X et al (2024) Distinct clinical features of urothelial carcinoma with low-expressing human epidermal growth factor receptor 2 status. Transl Androl Urol 13(11):2419\u20132429. https:\/\/doi.org\/10.21037\/tau-24-354","journal-title":"Transl Androl Urol"},{"issue":"1","key":"5110_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/his.15170","volume":"85","author":"H Zhang","year":"2024","unstructured":"Zhang H, Finkelman BS, Ettel MG, Velez MJ, Turner BM, Hicks DG (2024) HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls. Histopathology 85(1):3\u201319. https:\/\/doi.org\/10.1111\/his.15170","journal-title":"Histopathology"},{"issue":"12","key":"5110_CR49","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.ccell.2024.10.016","volume":"42","author":"H Hamidi","year":"2024","unstructured":"Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X et al (2024) Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell 42(12):2098\u20132112. https:\/\/doi.org\/10.1016\/j.ccell.2024.10.016","journal-title":"Cancer Cell"},{"issue":"4","key":"5110_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/iju.15376","volume":"31","author":"TY Yu","year":"2024","unstructured":"Yu TY, Wang HJ, Sung MT, Chuang YC, Chen YT, Cheng YT et al (2024) Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy. Int J Urol 31(4):410\u2013418. https:\/\/doi.org\/10.1111\/iju.15376","journal-title":"Int J Urol"},{"issue":"1","key":"5110_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","volume":"25","author":"HS Lee","year":"2025","unstructured":"Lee HS (2025) Spatial and temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers. J Gastric Cancer 25(1):192\u2013209. https:\/\/doi.org\/10.5230\/jgc.2025.25.e3","journal-title":"J Gastric Cancer"},{"key":"5110_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1723716","volume":"15","author":"Y Chen","year":"2025","unstructured":"Chen Y, Yang L, Qu W, Tu J, Cheng S, Guo X (2025) Deviating HER2 status between primary breast carcinomas and their liver metastases. Front Oncol 15:1723716. https:\/\/doi.org\/10.3389\/fonc.2025.1723716","journal-title":"Front Oncol"},{"issue":"4","key":"5110_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.clbc.2024.11.017","volume":"25","author":"S Bhardwaj","year":"2025","unstructured":"Bhardwaj S, Jaffer S (2025) A comparative analysis of the value of HER2 immunohistochemistry scoring in primary and metastatic breast cancer, in the era of HER2 \u201clow\u201d breast cancers. Clin Breast Cancer 25(4):354\u2013357. https:\/\/doi.org\/10.1016\/j.clbc.2024.11.017","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"5110_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01989-9","volume":"27","author":"FCA de Moraes","year":"2025","unstructured":"de Moraes FCA, de Castro Ribeiro CHD, Pess\u00f4a FDDL, Chaves JR, de Souza APB, Di Felipe \u00c1vila Alcantara D et al (2025) Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. Breast Cancer Res 27(1):39. https:\/\/doi.org\/10.1186\/s13058-025-01989-9","journal-title":"Breast Cancer Res"},{"key":"5110_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1011885","volume":"12","author":"E Scherrer","year":"2022","unstructured":"Scherrer E, Kang A, Bloudek LM, Koshkin VS (2022) HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol 12:1011885. https:\/\/doi.org\/10.3389\/fonc.2022.1011885","journal-title":"Front Oncol"},{"key":"5110_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00879","volume":"9","author":"VS Koshkin","year":"2025","unstructured":"Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H et al (2025) Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma. JCO Precis Oncol 9:e2400879. https:\/\/doi.org\/10.1200\/PO-24-00879","journal-title":"JCO Precis Oncol"},{"key":"5110_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903297","volume":"13","author":"HK Chae","year":"2022","unstructured":"Chae HK, Nam W, Kim HG, Lim S, Noh B, Kim SW et al (2022) Identification of new prognostic markers and therapeutic targets for non-muscle invasive bladder cancer: HER2 as a potential target antigen. Front Immunol 13:903297. https:\/\/doi.org\/10.3389\/fimmu.2022.903297","journal-title":"Front Immunol"},{"issue":"6","key":"5110_CR58","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/MOU.0000000000001330","volume":"35","author":"FM Bracco","year":"2025","unstructured":"Bracco FM, Wong CHM, Teoh JYC (2025) Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development. Curr Opin Urol 35(6):653\u2013660. https:\/\/doi.org\/10.1097\/MOU.0000000000001330","journal-title":"Curr Opin Urol"},{"key":"5110_CR59","unstructured":"ASCO GU 2024: HER2 and PD-L1 Immunohistochemistry Expression, and HER2 Genomic Alterations: Associations and Clinical Outcomes for Advanced Bladder Cancer; cited 2025\u201312\u201314]. Available from: https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2024\/asco-gu-2024-bladder-cancer\/149386-asco-gu-2024-her2-and-pd-l1-immunohistochemistry-expression-and-her2-genomic-alterations-associations-and-clinical-outcomes-for-advanced-bladder-cancer.html"},{"issue":"1","key":"5110_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-023-01295-y","volume":"18","author":"DS Helal","year":"2023","unstructured":"Helal DS, Darwish SA, Awad RA, Ali DA, El-Guindy DM (2023) Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival. Diagn Pathol 18(1):11. https:\/\/doi.org\/10.1186\/s13000-023-01295-y","journal-title":"Diagn Pathol"},{"issue":"1","key":"5110_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s43042-024-00618-y","volume":"25","author":"EM Naguib","year":"2024","unstructured":"Naguib EM, Ismail EF, Badran DI, Sherief MH, El-Abaseri TB (2024) Double trouble: how c-MET and HER2 fuel bladder cancer progression. Egypt J Med Hum Genet 25(1):147. https:\/\/doi.org\/10.1186\/s43042-024-00618-y","journal-title":"Egypt J Med Hum Genet"},{"issue":"3","key":"5110_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0390-8","volume":"17","author":"OMS El-Taji","year":"2016","unstructured":"El-Taji OMS, Alam S, Hussain SA (2016) Bladder sparing approaches for muscle-invasive bladder cancers. Curr Treat Options Oncol 17(3):15. https:\/\/doi.org\/10.1007\/s11864-016-0390-8","journal-title":"Curr Treat Options Oncol"},{"key":"5110_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233196","volume":"13","author":"F Wen","year":"2023","unstructured":"Wen F, Lin T, Zhang P, Shen Y (2023) RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib\/II study (HOPE-03). Front Oncol 13:1233196. https:\/\/doi.org\/10.3389\/fonc.2023.1233196","journal-title":"Front Oncol"},{"issue":"16_SUPPL","key":"5110_CR64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e12620","volume":"43","author":"X Liu","year":"2025","unstructured":"Liu X, Zhuang C, Song Y, He P, Zheng D, Yan X et al (2025) An exploratory clinical study investigating the neoadjuvant treatment of HER2-low expressing, stage II-III breast cancer with disitamab vedotin combined with penpulimab (RCVDBCIIR005). J Clin Oncol 43(16_SUPPL):e12620. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e12620","journal-title":"J Clin Oncol"},{"key":"5110_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67643-2","author":"Z Chen","year":"2025","unstructured":"Chen Z, Tang X, Eichholz JE, Mcpherson A, Thomas J, Nagar K et al (2025) Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-025-67643-2","journal-title":"Nat Commun"},{"key":"5110_CR66","doi-asserted-by":"crossref","unstructured":"Abstract a007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2\/HER2 status in urothelial cancer; cited 2025\u201312\u201314]. Available from: \/clincancerres\/article\/30\/10_Supplement\/A007\/745258\/Abstract-A007-Circulating-tumor-DNA-and-tissue","DOI":"10.1158\/1557-3265.BLADDER24-A007"},{"key":"5110_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.csbj.2024.10.007","volume":"26","author":"A Huang","year":"2024","unstructured":"Huang A, Zhao Y, Guan F, Zhang H, Luo B, Xie T et al (2024) Performance of a HER2 testing algorithm tailored for urothelial bladder cancer: a bi-centre study. Comput Struct Biotechnol J 26:40\u201350. https:\/\/doi.org\/10.1016\/j.csbj.2024.10.007","journal-title":"Comput Struct Biotechnol J"},{"key":"5110_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.euros.2024.02.006","volume":"62","author":"SH Han","year":"2024","unstructured":"Han SH, Camp SY, Chu H, Collins R, Gillani R, Park J et al (2024) Integrative analysis of germline rare variants in clear and non\u2013clear cell renal cell carcinoma. Eur Urol Open Sci 62:107\u2013122. https:\/\/doi.org\/10.1016\/j.euros.2024.02.006","journal-title":"Eur Urol Open Sci"},{"key":"5110_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203367","author":"T Somoto","year":"2025","unstructured":"Somoto T, Utsumi T, Ikeda R, Ishitsuka N, Noro T, Suzuki Y et al (2025) Navigating therapeutic landscapes in urothelial cancer: from chemotherapy to precision immuno-oncology. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17203367","journal-title":"Cancers (Basel)"},{"key":"5110_CR70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.humpath.2020.10.006","volume":"107","author":"CM Grigg","year":"2021","unstructured":"Grigg CM, Livasy C, He J, Hartman A, Clark PE, Zhu J et al (2021) Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. Hum Pathol 107:96\u2013103. https:\/\/doi.org\/10.1016\/j.humpath.2020.10.006","journal-title":"Hum Pathol"},{"key":"5110_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.04.161","author":"J Ye","year":"2024","unstructured":"Ye J, Zhang M, Bao Y (2024) Discordance of HER2 expression in primary and recurrent\/metastatic urothelial carcinoma in the upper tract. Asian J Surg. https:\/\/doi.org\/10.1016\/j.asjsur.2024.04.161","journal-title":"Asian J Surg"},{"issue":"1","key":"5110_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/03008916231186178","volume":"110","author":"J Ye","year":"2024","unstructured":"Ye J, Liao X, Qiu Y, Wei Q, Bao Y (2024) A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients. Tumori 110(1):25\u201333. https:\/\/doi.org\/10.1177\/03008916231186178","journal-title":"Tumori"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05110-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05110-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:40:16Z","timestamp":1787654416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05110-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":72,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05110-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}